Intercept Pharma (ICPT) Misses Q1 EPS by 52c; Revenues Beat; Raises FY19 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
May 8, 2019 7:01 AM EDTPositive results from pivotal Phase 3 REGENERATE study of OCA in patients with liver fibrosis due to NASH
New Drug Application (NDA) filing in the U.S. for OCA in NASH projected in the third quarter of 2019Â
Worldwide Ocaliva net sales of $51.8 million in the first quarter of 2019 representing 47% growth versus the prior year quarterÂ
Increasing 2019 Ocaliva net sales guidance range to between $235 and $245 millionÂ
Updating 2019 non-GAAP adjusted operating expenses guidance range to between $470 and $500... More
